iBio Inc. Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Tables)

12 Months Ended

Jun. 30, 2019

The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):


	Years ended
	June 30,
	2019		2018
Basic and diluted numerator:

Net loss attributable to iBio, Inc. stockholders	$	(17,593)	$	(16,105)
Preferred stock dividends		(260)		(260)
Net loss available to iBio, Inc. stockholders	$	(17,853)	$	(16,365)

Basic and diluted denominator:

Weighted-average common shares outstanding		18,926		10,631

Per share amount	$	(0.94)	$	(1.54)

As of June 30, 2019 and 2018, shares issuable which could potentially dilute future earnings included were as follows.


	Year Ended
	June 30,
	2019	2018
	(in thousands)
Stock options	1,347	1,365
Series A Preferred	4,430	6,900
Series B Preferred	6,428	6,428
Shares excluded from the calculation of diluted loss per share	12,205	14,693